In this video, Fluke expert Corey Glassman explains how to get your Wireless CNX system set up. If you haven't seen CNX in action, this is a great video demonstrating how the modules work together to provide remote, simultaneous and recordable readings.
At the core of the Fluke CNX Wireless System is a CAT III 1000 V / CAT IV 600 V multimeter with a screen that displays its readings along with live readings from up to three other measurement modules. For more complex troubleshooting, users can view live measurements from up to 10 modules simultaneously on a computer equipped with the CNX PC Adapter.
The modules, which include AC Voltage, AC Current Clamp, iFlex AC Current Clamp, and K-Type Temperature units, can take live measurements or log up to 65,000 sets of data. Logged data can be saved to a computer in .csv format.
LifeProof, the award-winning maker of all-protective, everyday cases for smartphones and tablets, today announced the availability of the LifeProof nüüd and frē cases for the Samsung Galaxy S III. The latest member of the LifeProof family, and the first case offered for Android smartphones, provides users the same waterproof, drop proof, dirt proof and snow proof protection as every LifeProof case and features a clear back that allows users to show off the phone’s color and design.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58924-lifeproof-samsung-galaxy-s-iii-has-arrived-all-protective-case
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Golf Lessons Irvine http://www.GolfSwingPrescription.com Call (949) 554-9926 - Are you looking for golf lessons in Irvine (or the nearby area) or just golfing tips in general? Ryan Trengrove (Class A PGA member), owner of a state-of-the-art indoor golf training facility called Golf Swing Prescription (Laguna Hills, CA), shows you how conquer one of the most common problems in Golf - keeping your lower body stable while swinging the golf club!
Ryan states that if you can get your lower body to be more stable, you will have a lot more fun when you are playing golf. Ryan shows you a video of one of Golf’s great player’s, Davis Love III, to display great lower body stability. Ryan points out how Davis’s lower body not only stays in the “same sit” and “same flex” as Davis goes up to the top of his golf swing, but, also when he goes back down to hit the golf ball.
Ryan also points out the importance of NOT having your lower body “sway”, but to have it “swivel” instead. The goal is to keep the lower body in its flex, so that you can have it sit, and keep the hip in the same spot. If you are able to do this, as you come from the top of your swing down to the ball, you should make solid contact.
In order to assist you in achieving better lower body stability, Ryan shows you a golf drill called the “Feet Together Drill”. This drill has the golfer setup to hit the golf ball with their feet together, which will prevent the golfer from going “side to side” during the swing. The idea behind the drill is to have the golfer hit a number of shots with their feet together so that they can get the “feeling” of not “going side to side” and being stable. Once you get use to the feeling, then you can widen your golf stance, trying to maintain the same “stable feeling” felt during the drill, with your base “swiveling” and not “swaying”.
Ryan goes on to show you one more drill to help you that he got from Golf Professional, Nick Faldo called the “Right Foot Forward – Left Leg Back Drill” (just switch if you are left handed). The goal of this drill is to help you focus on keeping the flex in your right knee. You get in your normal golf stance, but, just move your left leg back a couple of feet, and then hit the ball. So what this drill does is to focus you on keeping the proper flex in your right knee.
What Ryan wants you to do is to work on the combination of the “Feet Together Drill” and the “Right Foot Forward –Left Leg Back Drill” so that when you get up to your golf ball you focus on staying centered – no “side to side” and keeping your right knee flexed. Ryan points out that if you can do this, that you should make better contact with the ball!
Ryan performs over 1,500 golf lessons per year, when compared to the average club pro that only conducts approximately 300. Ryan is extremely popular for a reason; his indoor
The III Moscow International Forum for Innovative Development "Open Innovations" and the Open Innovations Expo in 2014 were organized by Russia in partnership with the People's Republic of China. On 14 October the heads of governments of the two countries held a plenary session -"The Emerging Global Innovation Map: Closing the Gap Between Countries." International cooperation was also discussed during the event "Innovation Dialogue: Partners Interaction Over Innovation Policy".
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762574-open-innovations-expo-moscow/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Gleich zweimal fallen erstmals Kindersitze der Traditionsmarke Römer beim aktuellen Test des ADAC und der Stiftung Warentest mit „mangelhaft“ durch. Ein Sitz versagt beim Frontaufprall, der andere hat viel zu hohe Schadstoffwerte. Insgesamt erhalten vier von 15 getesteten Sitzen das ADAC Urteil „mangelhaft“. Bei einem Sitz von Axkid reißt sogar die Isofixverankerung, bei einem Sitz von Nania wird das Kind beim Seitenaufprall ungeschützt an die Autotür gedrückt. Generell gibt es dieses Mal auffallend viele schlechte Modelle. Als bestes Produkt im Test erweist sich der Cybex Juno 2-Fix mit einer sehr guten Beurteilung. Dieser wird mit Fangkörper in der Klasse I für Kinder von etwa 1 bis 4 Jahren angeboten, er ist damit besonders empfehlenswert. Da allerdings nicht jedes Kind einen Fangkörper akzeptiert, sollten Eltern dies vor dem Kauf unbedingt ausprobieren. Folgende Sitze erhalten ein „gut“ und sind empfehlenswert: Der Casualplay Q-Retraktor Fix und der Casualplay Q-Retraktor Fix & Support Leg (mit Stützfuß) für die Klasse I (von etwa 1 bis 4 Jahren) sowie der Römer Kidfix XP SICT, der Recaro Monza Nova 2, der Storchenmühle Solar und der Recaro Monza Nova 2 Seatfix, alle für die Klasse II/III (von etwa 4 bis 12 Jahren). Beim Römer Xtensafix (Klasse I/II/III von etwa 1 bis 12 Jahren) rutscht der Gurt beim Crashtest aus der Führung und schneidet in den Hals des Kindes ein, was ein hohes Verletzungsrisiko darstellen kann – der Club bewertet deshalb das Produkt als „mangelhaft“. Auch der rückwärts gerichtete Römer Max-Fix (Klasse 0+/I, bis etwa 4 Jahre), ein sogenannter Reboarder, erhält aufgrund seiner hohen Schadstoffbelastung das ADAC Urteil „mangelhaft“. Durchgefallen sind auch die Babyschale Nania Baby Ride (bis etwa 1,5 Jahre) und der Axkid Kidzofix (Klasse I/II von etwa 1 bis 7 Jahren). Während die Babyschale beim Seitenaufprall versagt und das Kind bei einem Unfall ungeschützt an die Fahrzeugtüre geprallt wäre, reißt beim Axkid die Isofixverankerung im Frontcrash und der Sitz fliegt durch das Fahrzeug. Darüber hinaus ist dieser Sitz hoch belastet mit Schadstoffen. Die vollständigen ADAC Kindersitztestergebnisse sind unter www.adac.de/kindersitztest zu finden. Getestet wurden die Kindersitze aus allen Gewichtsklassen in den Kriterien Sicherheit, Bedienung & Ergonomie, Schadstoffgehalt, Reinigung und Verarbeitung. Wichtig für die Eltern: Die Kleinsten müssen bei jeder Fahrt im Sitz richtig gesichert sein. Vor dem Kauf sollte man sich unbedingt Bedienung und Einbau erklären lassen. Um Fehler beim Einbau zu vermeiden, muss die Bedienungsanleitung genau befolgt werden. Außerdem empfiehlt der ADAC, den Sitz vor dem Kauf im eigenen Fahrzeug auszuprobieren: Nicht jedes Produkt passt optimal in jedes Auto. Der Kindersitz muss sich stabil befestigen lassen und besonders auf den richtigen Gurtverlauf ist zu achten.
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Yankee Candle Company, Inc., the world’s largest manufacturer of premium scented candles, today announced the launch of two new fragrances and the return of three favorites in its popular limited edition Man Candles collection. Just in time for Father’s Day, Camouflage and On Tap™ join last year’s introduction MMM, Bacon!™ and original Man Candles Man Town™ and Riding Mower™. The Man Candles collection, which was an instant hit when it debuted in 2012, was created uniquely for men to enjoy in their “man town,” wherever that may be in the house. These limited edition fragrances are available now at Yankee Candle’s over 500 retail stores, at www.yankeecandle.com and select specialty retailers and gift shops. Yankee Candle is launching a series of social media contests offering consumers the chance to win samples of the Man Candles III collection!
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7221651-yankee-candle-heads-outdoors-new-man-candles-fragrances
Living Off the Grid - http://www.thriveoffthegrid.com/ - See how others are living offgrid using the advantages of wind and solar energy plus more for off grid power and ...
Living off the grid you must take advantage of renewable energy. This renewable resource originates from several sources, consisting of sun, wind and water, to start with ...
Researchers are constantly on the lookout for more ways of making green energy. Here are the 2 types you must understand now.
Living off the Grid: - Advantages of Solar Power
i. The energy that originates from simply one hour of sun suffices to supply energy for a year for the whole world
ii. A battery can be used to store off grid solar power for evenings and cloudy days
iii. Solar panels on a roof work when the sun's rays strike the cells in the panel and electrons are released, producing energy
iv. Using solar power will typically provide a saving of $100+ each month on utility costs for the property owners of off grid homes .
Living off the Grid: - Advantages of Wind Energy
i. When wind goes through the blades of a turbine that is connected to a generator, the energy produced by the spin is converted into electrical energy
ii. A single large wind turbine can provide electricity for around 500 off grid homes
iii. Last year, 42 % of the houses that were geared up with a source of off grid power used wind
iv. Unlike most other sources of energy, wind utilizes hardly any water; not only is wind energy carbon neutral, it helps water conservation also
v. There is around 10 times the amount of wind available in the U.S. than is needed to supply power for the whole country
vi. Wind energy is presently the fastest-growing source of renewable energy: - Around two wind farms are set up weekly in the U.S.
For living off the grid, the facts indicate that the advantages of solar power combined with the advantages of wind energy now exceed any advantages that fossil fuels may have had. However it is probably down to individuals to begin the shift to a larger scale adoption, so that we may all enjoy living off the grid.
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
